Cargando…

The comparative efficacy and safety of cholinesterase inhibitors in patients with mild‐to‐moderate Alzheimer's disease: a Bayesian network meta‐analysis

BACKGROUND: Comparative evidence for efficacy and safety of second‐generation cholinesterase inhibitors (ChEIs) is still sparse. OBJECTIVES: The purpose of this research is to compare three ChEIs, donepezil, galantamine and rivastigmine, in patients with mild‐to‐moderate Alzheimer's disease (AD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Hisanori, Ohnishi, Takashi, Nakagawa, Ryoko, Yoshizawa, Kazutake
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084309/ https://www.ncbi.nlm.nih.gov/pubmed/26680338 http://dx.doi.org/10.1002/gps.4405

Ejemplares similares

Long-term effect of galantamine on cognitive function in patients with Alzheimer’s disease versus a simulated disease trajectory: an observational study in the clinical setting
por: Nakagawa, Ryoko, et al.
Publicado: (2017)

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
por: Nakagawa, Ryoko, et al.
Publicado: (2015)

Cholinesterase inhibitors as Alzheimer's therapeutics
por: Sharma, Kamlesh
Publicado: (2019)

Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy
por: Wattmo, Carina, et al.
Publicado: (2016)

Cognitive and Affective Changes in Mild to Moderate Alzheimer’s Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A 6-Month Observational Study
por: Spalletta, Gianfranco, et al.
Publicado: (2014)

Good rate of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease after three months of treatment: An open-label study
por: de Miranda, Luis Felipe José Ravic, et al.
Publicado: (2013)

The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer’s Disease
por: Ohnishi, Takashi, et al.
Publicado: (2014)

Prescribing cholinesterase inhibitors in mild cognitive impairment—Observations from the Alzheimer's Disease Neuroimaging Initiative
por: Stage, Eddie, et al.
Publicado: (2021)

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
por: Hu, Ziheng, et al.
Publicado: (2018)

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy
por: Landen, Jaren W., et al.
Publicado: (2017)

Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
por: Han, Hyun Jeong, et al.
Publicado: (2011)

Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A Post Hoc Analysis of the EVOLUTION Study
por: Colombo, Delia, et al.
Publicado: (2018)

The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double-blind, placebo-controlled trial
por: Chen, Christopher L.H., et al.
Publicado: (2019)

Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan
por: Ueda, Kengo, et al.
Publicado: (2019)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease
por: Weng, Pei-Hsuan, et al.
Publicado: (2013)

Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer’s Disease
por: Hussein, Weiam, et al.
Publicado: (2018)

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease
por: Motter, Jeffrey N., et al.
Publicado: (2021)

Comparison of cholinesterase inhibitor safety in real-world practice
por: Carney, Greg, et al.
Publicado: (2019)

Effectiveness of Nootropics in Combination with Cholinesterase Inhibitors on Cognitive Function in Mild-to-Moderate Dementia: A Study Using Real-World Data
por: Kang, Minjae, et al.
Publicado: (2022)

Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis(1)
por: Yunusa, Ismaeel, et al.
Publicado: (2021)

Erratum to: Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis
Publicado: (2021)

The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors
por: Grossberg, George T., et al.
Publicado: (2013)

Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials
por: Raschetti, Roberto, et al.
Publicado: (2007)

Safety and efficacy of donepezil hydrochloride in patients with mild to moderate Alzheimer's disease: Findings of an observational study
por: Mehta, Suyog, et al.
Publicado: (2012)

Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer’s Disease
por: Schino, Ignazio, et al.
Publicado: (2022)

Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin
por: Nakayama, Masahiko, et al.
Publicado: (2015)

Estimation of minimal clinically important change of the Japanese version of EQ-5D in patients with chronic noncancer pain: a retrospective research using real-world data
por: Yoshizawa, Kazutake, et al.
Publicado: (2016)

Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials
por: Nakayama, Masahiko, et al.
Publicado: (2016)

Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan
por: Nakayama, Masahiko, et al.
Publicado: (2018)

Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials
por: Dou, Kai-Xin, et al.
Publicado: (2018)

Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis
por: Caro, Jaime, et al.
Publicado: (2003)

Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet
por: Monteiro, Cecilia, et al.
Publicado: (2023)

A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease
por: S. Schneider, Lon
Publicado: (2000)

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
por: Rountree, Susan D, et al.
Publicado: (2009)

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
por: Farrimond, Lucy E, et al.
Publicado: (2012)

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
por: Wattmo, Carina, et al.
Publicado: (2012)

Screening and analysis of acetyl-cholinesterase (AChE) inhibitors in the context of Alzheimer's disease
por: Khan, Mohd. Babu, et al.
Publicado: (2018)

Effect of QT Prolongation in Patients Taking Cholinesterase Inhibitors (Donepezil) for Alzheimer’s Disease
por: Kuwahata, So, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_flucsmee07jevcib2g65e6sts0